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Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease and is associated with poor
clinical outcome following traumatic brain injury and other neuropathological disorders. Protein instability
and an isoform-specific apoE property called domain interaction are responsible for these neuropathological
effects. ApoE4 is the most neurotoxic isoform and can induce neuropathology through various cellular
pathways. Neuronal damage or stress induces apoE synthesis as part of the repair response; however,
when apoE4 is expressed in neurons, its unique conformation makes it susceptible to proteolysis, resulting
in the generation of neurotoxic fragments. These fragments cause pathological mitochondrial dysfunction
and cytoskeletal alterations. Here, we review data supporting the hypothesis that apoE4 (> apoE3 > apoE2)
has direct neurotoxic effects and highlight studies showing that blocking domain interaction reverses these
detrimental effects.INTRODUCTION
Apolipoprotein (apo) E was originally described in the early
1970s as a protein constituent of cholesterol-and triglyceride-
rich plasma lipoproteins synthesized by the liver. Its expression
is induced by cholesterol-rich diets in a large variety of animals
and is enriched in lipoproteins in humans with the genetic
disorder type III hyperlipoproteinemia (Mahley, 1988; Mahley
and Rall, 2000; Mahley et al., 2009). ApoE circulates in the
blood as a protein component of very low density lipoproteins,
chylomicron remnants, and a subclass of high density lipopro-
teins, as well as in the cerebrospinal fluid and central nervous
system interstitial fluid on small particles and disks resembling
high density lipoproteins. ApoE is responsible for the transport
of cholesterol and other lipids, as well as for mediating the
clearance of plasma lipoproteins by serving as a critical ligand
for lipoprotein uptake by the low density lipoprotein (LDL)
receptor and LDL receptor-related protein family members.
Furthermore, apoE participates in the redistribution of lipids to
cells that require cholesterol and phospholipids for reparative
processes throughout the body, including the central nervous
system.
Human apoE is a polymorphic protein arising from three alleles
at a single gene locus on chromosome 19 (Mahley, 1988; Mahley
and Rall, 2000; Mahley et al., 2009). The three major isoforms—
apoE2, apoE3, and apoE4—differ from one another by single
amino acid interchanges at just two residues; however, these
minor changes have profound effects on the structure and func-
tion of apoE at both the molecular and cellular levels and, as
a consequence, on their association with specific diseases,
including Alzheimer’s disease (AD).The pioneering work of Roses and associates during the early
1990s established, through a genetic linkage study, the very
strong association between apoE4 and AD (Corder et al., 1993;
Saunders et al., 1993; Strittmatter et al., 1993). Expression of
the apoE4 allele significantly increases the risk of developing
AD during one’s lifetime (by 4- to 12-fold compared with
apoE3/3 individuals) and decreases the age of onset (by approx-
imately 8 years to 15 years in apoE4 heterozygotes and homozy-
gotes, respectively). It is now established that apoE4 is a major
AD gene with semidominant inheritance in apoE4 homozygotes,
equivalent to the BRAC1 gene for breast cancer (Genin et al.,
2011), making it the strongest genetic risk factor for AD by
far (Farrer et al., 1997). Although the data are not as strong as
with AD, apoE4 has also been associated with progression
or poor clinical outcomes in traumatic brain injury (TBI) (Chame-
lian et al., 2004; Crawford et al., 2002; Friedman et al., 1999;
Gandy and DeKosky, 2012; Mayeux et al., 1995; Nicoll et al.,
1996; Teasdale et al., 1997), multiple sclerosis (Chapman et al.,
2001; Fazekas et al., 2001), stroke (Alberts et al., 1995; McCar-
ron et al., 1999; Slooter et al., 1997), frontotemporal dementia
(Agosta et al., 2009), and Parkinson’s disease (Harhangi et al.,
2000; Li et al., 2004; Martinez et al., 2005; Parsian et al., 2002).
Furthermore, apoE4 is not rare—approximately 25% of all indi-
viduals are carriers of this allele—making the potential detri-
mental effects of apoE4 expression all too common. Indeed,
the apoE4 allele is heavily enriched in AD patients, with 65%–
80% of all AD patients carrying at least one copy (Farrer et al.,
1997).
The neuropathological effects of apoE4—the least stable
of the three isoforms and the most tightly associated with
AD—aremyriad and include the following (for review, see Huang,Neuron 76, December 6, 2012 ª2012 Elsevier Inc. 871
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outgrowth; (2) cytoskeletal disruption and hyperphosphoryla-
tion of tau; (3) mitochondrial dysfunction in neurons, including
altered membrane potential, reduced mitochondrial motility,
and decreased mitochondrial respiratory enzyme levels and
activity; (4) impaired synaptogenesis; (5) increased amyloid
b (Ab) production; (6) increased lysosomal leakage and
apoptosis in neurons; (7) brain neuropathology and impaired
learning and memory in mice; and (8) altered Ab peptide clear-
ance and/or deposition.
The premise of this review is that the structural differences
among the apoE isoforms determine their roles in the onset
and progression of AD and other neurodegenerative diseases
and that modulation of the abnormal structure of apoE4—by
converting it to a more apoE3-like (or apoE2-like) structure—
will reverse the apoE4-associated detrimental effects in the
central nervous system (Mahley and Huang, 2012). First, how-
ever, we discuss how apoE may indirectly impact neuropa-
thology in AD through modulation of Ab metabolism, before
moving on to present the apoE hypothesis more fully and the
most recent evidence describing the direct effects of apoE
(apoE4 > apoE3 > apoE2) in the pathogenesis of neurodegener-
ative disorders.
ApoE Modulation of the Ab Pathway
The amyloid hypothesis focuses on the effects of the Ab peptide
and its different assemblies in causing neuropathology, disrupt-
ing synaptic connections and forming plaques (Hardy, 2006;
Palop et al., 2006; Palop andMucke, 2010; Selkoe, 2011). Impor-
tantly, it is established that there are apoE isoform-specific
effects on the Ab pathway (Huang and Mucke, 2012; Kim
et al., 2009; Selkoe, 2011) and that apoE4 expression is associ-
ated with a significant increase in amyloid plaques at earlier ages
comparedwith apoE3 or apoE2. Furthermore, apoE4 is known to
impair Ab clearance (Bien-Ly et al., 2011; Castellano et al., 2011;
Deane et al., 2008; Kim et al., 2011) and accelerate amyloid
synthesis (Ye et al., 2005), as well as amyloid fibril formation
and deposition (Bales et al., 1999; Bien-Ly et al., 2011; Sanan
et al., 1994; Wisniewski et al., 1995).
ApoE protein levels in the cerebrospinal fluid and brain have
been correlated with Ab levels and related to apoE isoform-
specific effects (Beffert et al., 1999). For example, comparison
of human apoE3 and apoE4 knockin mice demonstrated that
apoE4 levels were 30%–40% lower than apoE3 levels in the
cortex, hippocampus, and cerebellum (Ramaswamy et al.,
2005). One explanation for this reduction in apoE4 expression
was revealed by Zhong et al. (2009), who demonstrated that
apoE4 domain interaction activates the endoplasmic reticulum
(ER) stress response in astrocytes, which results in the degrada-
tion of apoE4. Could this suggest that increasing apoE levels is
protective?
Consistent with the postulate that increasing apoE levels
could be beneficial, Cramer et al. (2012) demonstrated that
induction of mouse apoE expression in an AD mouse model
using the RXR agonist bexarotene led to a short-term reduction
in soluble Ab and plaque loads (i.e., within 72 hr of initiating
treatment). However, after 3 months of oral treatment they
observed no change in amyloid burden. While these are poten-872 Neuron 76, December 6, 2012 ª2012 Elsevier Inc.tially important observations, a number of questions remain.
First, can one equate the effect of increasing mouse apoE to
that of the human apoE isoforms? Mouse apoE is neither struc-
turally nor functionally equivalent to human apoE3 or apoE4
(Zhong and Weisgraber, 2009) and behaves differently from
the human isoforms with respect to Ab clearance (Bien-Ly
et al., 2011). Importantly, it was recently reported that geneti-
cally increasing either human apoE3 or apoE4 levels increased
Ab accumulation (Bien-Ly et al., 2012; Kim et al., 2011). Second,
would it be beneficial to increase apoE4 levels in the brains of
patients? As discussed later, numerous studies demonstrate
that apoE4 has detrimental effects in the central nervous system
(CNS). Finally, bexarotene is known to regulate numerous genes
related to lipid metabolism, thus further complicating the inter-
pretation of the data.
Others have emphasized the protective role for apoE3 in the
context of amyloid metabolism, postulating that apoE4 lacks
the beneficial effects of apoE3. Clearly apoE3 does possess
beneficial effects (Kim et al., 2009; Mahley et al., 2006). For
example, apoE3 is more effective than apoE4 in mediating Ab
clearance from mouse brains (Kim et al., 2009). It also has
been demonstrated that apoE3 suppresses inflammation better
than apoE4 (Lynch et al., 2003). In contrast, apoE4 has been
shown to stimulate proinflammatory cytokines and exacerbate
inflammation to a greater extent than apoE3 (Guo et al., 2004).
Interestingly, apoE mimetics, which are small peptides corre-
sponding to the apoE receptor-binding region, appear to mimic
the anti-inflammatory activity of apoE3 and have been shown to
improve cognitive performance and neuronal survival in TBI
mouse models (Vitek et al., 2012). However, the mechanism by
which these peptides work remains to be defined.
It is now recognized that there are multiple factors acting
through various pathways to cause cognitive decline and neuro-
degeneration in AD (Huang, 2010; Huang and Mucke, 2012; Kim
et al., 2009; Mahley et al., 2006). ApoE clearly interacts with
the Ab pathway; however, there is abundant evidence showing
that apoE (apoE4 > apoE3 > apoE2) also can directly impact
the pathogenesis of AD and other neurodegenerative disorders
independent of Ab. As clinical trials targeting the lowering of
amyloid and the Ab peptide fail to impact AD cognitive decline
and neurodegeneration (Selkoe, 2011), alternative mechanisms
must be considered, and the critical importance of apoE in path-
ogenesis further acknowledged.
Direct Effects of ApoE in Causing Neuropathology
Under normal physiological conditions, apoE is synthesized
primarily by astrocytes in the brain to support lipid transport
and membrane repair processes (Mahley, 1988). In contrast,
apoE synthesis in neurons usually occurs in response to neu-
ronal insult or injury. Each of these processes is designed
to protect neuronal integrity and promote neuronal repair,
respectively, but in fact can be directly injurious when apoE4
is expressed in neurons. Indeed, apoE4 expression is asso-
ciated with poor clinical outcome or accelerated/more severe
progression in numerous neurological disorders. This finding
strongly suggests that while apoE participates in general cellular
pathway(s) designed to respond adaptively to various environ-
mental, metabolic, or genetic stimuli, its expression can also
Figure 1. Injurious Agents that Stress or Damage Neurons Induce
ApoE Synthesis and Initiate Neuropathology
ApoE4, because of domain interaction, displays impaired trafficking through
the ER and Golgi apparatus compared with apoE3. As a result, it is targeted to
a neuron-specific protease that initially cleaves off the C-terminal 27–30 amino
acids, generating neurotoxic fragments. These fragments escape the secre-
tory pathway and enter the cytosol, where they cause mitochondrial dys-
function and cytoskeletal alterations, enhance tau phosphorylation, and form
neurofibrillary tangle-like NFT-like structures (Mahley et al., 2006). Figure
reprinted with permission from Mahley and Huang (2012). Copyright 2012
American Chemical Society.
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for this have been suggested.
ApoE is known to exhibit isoform-specific effects on blood-
brain barrier (BBB) integrity in mouse models (Bell et al., 2012).
In either target replacement mice or glial fibrillary acidic protein
promoter transgenic mice, apoE4 expression increases the
BBB’s susceptibility to injury by activating the proinflammatory
cytokine cyclophilin A in pericytes and triggering the NF-kB/
matrix metalloproteinase 9 pathway. Interestingly, BBB break-
down is independent of Ab. The subsequent neuronal damage
that occurs appears to result from the leakage of blood-derived
proteins—including immunoglobulin G, thrombin, and fibrin—
into the brain. The extravasation of blood proteins has been
implicated in the activation of numerous neurotoxic pathways.
For example, in a mouse model of multiple sclerosis, fibrinogen
leakage and fibrin deposition in the brain activate microglia and
lead to neuropathology (Adams et al., 2007; Akassoglou et al.,
2004; Davalos and Akassoglou, 2012). As will be discussed,
BBB leakage could represent an additional insult linked to neu-
ronal injury and the induction of neuronal apoE synthesis and
neurotoxicity.
ApoE is also involved in maintaining and regulating synaptic
activity and strength in knockin mice and hippocampal slices.
Specifically, apoE4 reduces neuronal cell-surface expression
of the apoE receptor 2, as well as N-methyl-D-aspartate and
AMPA receptors, by sequestering them in an intracellular
compartment (Chen et al., 2010). It is postulated that the apoE
isoform-specific effect on lipoprotein and glutamate receptor
trafficking contributes to AD neuropathology by impairing syn-
aptic activity. In addition, other LDL receptor family members
have been implicated in AD, owing to their roles in modulating
the intracellular trafficking and processing of the amyloid pre-
cursor protein (Cam and Bu, 2006).
The effects of astrocyte-derived apoE in the brain are a point of
ongoing study, and it remains to be described whether astro-
cyte-derived apoE impacts neuronal health and pathology differ-
ently from the apoE that is synthesized within neurons. The
remainder of this review will describe how induction of neuronal
apoE (apoE4 > apoE3 > apoE2) in response to injury sets the
stage for neuropathology and subsequent neurodegeneration.
The ApoE Hypothesis: Relationship between ApoE
Structure, Function, and Expression in Health and
Disease
The apoE hypothesis posits that apoE genotype sets the stage
for neuropathology in an isoform-dependent manner (apoE4 >
apoE3 > apoE2), and ‘‘second hits’’ that directly induce neuronal
injury or stress initiate a pathological response to injury when
apoE4 is synthesized in neurons (Huang, 2010; Huang and
Mucke, 2012; Mahley and Huang, 2012; Mahley et al., 2006).
With respect to AD, these second hits could include aging,
ischemia, trauma, inflammation, oxidative stress, or toxins like
the Ab peptide and its different assemblies. TBI causes direct
damage to neurons, whereas following stroke the second hit
may be ischemia. Given the nature of many neurological
diseases, where multiple pathologies occur over a protracted
period, the possibility for second hits is very high. Other genetic
disorders and metabolic disturbances, such as diabetes, canalso be injurious factors that contribute to apoE4’s neurotoxic
effects.
In response to injury, neurons induce the synthesis of apoE,
presumably to participate in lipid transport and redistribution
for membrane repair and remodeling. However, because of
varying degrees of structural instability and tendency to assume
domain interaction across the apoE isoforms (which we discuss
in greater detail below), apoE can be recognized as struc-
turally abnormal by neurons and undergo proteolytic cleavage
(apoE4 > apoE3 > apoE2). The neurotoxic fragments that are
generated cause mitochondrial dysfunction and cytoskeletal
alterations. In the sections to follow, we describe in more detail
the data supporting the apoE hypothesis (Figure 1).
Neuronal Injury Induces ApoE Synthesis: A ‘‘Hair-
Trigger’’ Mechanism Allows for Rapid Production
As mentioned previously, in the brain apoE is primarily synthe-
sized by astrocytes under normal physiological conditions (Mah-
ley, 1988) and the neuropathological effects of astrocyte-derived
apoE are a point of ongoing study. However, apoE can also be
produced by neurons under pathological conditions resulting
from neuronal cell injury or stress (Huang, 2010; Huang and
Mucke, 2012; Mahley et al., 2006). Xu et al. (2006) established
an enhanced green fluorescent protein (EGFP)apoE-reporter
mouse model in which EGFP was inserted into one allele of the
apoE gene to serve as a reporter of apoE expression. The hippo-
campus of a normal, uninjured mouse brain showed abundant
EGFP expression in astrocytes, but little expression of EGFP in
neurons, indicating no or very low neuronal apoE production
(Figure 2). However, following kainic acid-induced excitotoxic
injury, apoE production was markedly increased in damagedNeuron 76, December 6, 2012 ª2012 Elsevier Inc. 873
Figure 2. EGFP Inserted into One Allele of the ApoE Gene Acts as
a Marker for ApoE Expression in Vivo
Top, schematic of the EGFP-apoE reporter cassette. Bottom, representative
images of hippocampal sections taken from EGFPapoE-reporter knockin
mice. In the uninjured mouse hippocampus (before kainic acid), astrocytes
display abundant apoE expression (bottom, left); however, after injury with
kainic acid, neurons turn on the synthesis of apoE, as indicated by the
colocalization of EGFP (green) and NeuN (red) (bottom, right). Modified from
Xu et al. (2006).
Figure 3. Kainic Acid-Induced Injury Triggers Switch from Intron
3-Containing to Mature ApoE mRNA Synthesis
EGFPapoE-reporter knockin mice were treated or not with kainic acid, and CA1
hippocampal neurons were isolated by laser-capture microdissection for
reverse transcription-polymerase chain reaction (RT-PCR). Neurons from a
normal, uninjured mouse demonstrate the presence of apoEmRNA with intron
3 (apoE-I3), whereas after injury there is a dramatic switch to mature apoE
mRNA lacking intron 3. Modified from Xu et al. (2008).
Neuron
Perspectivehippocampal neurons, as measured using the EGFP reporter as
the readout (Figure 2). In addition, both apoE mRNA and protein
were expressed in hippocampal neurons following kainic acid
treatment, as shown by in situ hybridization and immunochem-
istry, respectively (Xu et al., 2006).
Further studies revealed that the mechanism controlling the
synthesis of apoE in neurons is unique and poised for rapid
protein production (Xu et al., 2008). These studies found that
while little apoE protein is seen in uninjured neurons, the apoE
gene is still transcribed; however, in these uninjured neurons
intron 3 is typically left intact in the transcribed mRNA sequence,
leading to its retention and degradation in the nucleus. However,
following kainic acid-induced injury, intron 3 was spliced out,
resulting in mature apoE mRNA being transferred out of the
nucleus for apoE protein production in neurons. In situ hybridiza-
tion studies in uninjured mouse brains revealed that hippo-
campal neurons almost exclusively expressed intron 3-contain-
ing apoE mRNA, while hippocampal astrocytes expressed the
intron 3-lacking apoE transcript in abundance (Xu et al., 2008).
Laser-capture microdissection studies in the hippocampus of
uninjured mice also revealed the presence of intron 3-containing
apoEmRNA; however, after injury there was a dramatic switch in
expression to intron 3–lacking, mature apoE mRNA (Figure 3).
This phenomenon is unique to neurons, as apoE intron retention
has not been observed in other apoE-synthesizing cell types.
In addition, astrocyte-conditioned medium can trigger the syn-
thesis of apoE in neurons, revealing an important ‘‘crosstalk’’
between neurons and glia that is likely to operate during an injury
response (Harris et al., 2004b). Thus, neurons possess a unique
mechanism whereby they are primed for the rapid production of
apoE. The splicing and nuclear export pathways that regulate
mRNA and protein production operate ubiquitously in eukaryotic
cells and are modulated, in part, through stress; however, these
pathways remain to be fully understood (Cullen, 2000; Fox and
Lamond, 2010; Galy et al., 2004; Prasanth et al., 2005).874 Neuron 76, December 6, 2012 ª2012 Elsevier Inc.Why might injured neurons turn on the synthesis of apoE and
appear to be primed for apoE secretion? Lipid metabolism is
unique in the brain for two reasons. First, apoE is the only apoli-
poprotein present in the brain that binds to the LDL receptor
or members of the LDL receptor family, which are responsible
for delivering cholesterol and other complex lipids to central
nervous system cells through receptor-mediated endocytosis
(Bu, 2009; Herz and Bock, 2002; Mahley and Rall, 2000; Mahley
et al., 2009). Second, complex lipids are almost totally synthe-
sized de novo by the various brain cells and very little of these
lipids, including cholesterol, are delivered from the periphery
by exchange or uptake of plasma lipoproteins across the BBB
(Dietschy and Turley, 2001).
The redistribution of complex lipids for membrane repair and
other metabolic roles undoubtedly relies on apoE through a
process termed secretion-capture (Ji et al., 1994; Mahley and
Ji, 1999; Mahley et al., 2009), in which secreted apoE scavenges
lipids from the local environment and targets them to cells
requiring lipids for normal metabolism or membrane repair.
The secretion-capture role for apoE was first demonstrated in
peripheral nerve injury and regeneration (Boyles et al., 1989;
Ignatius et al., 1987; Mahley, 1988) and later in the CNS follow-
ing hippocampal injury (Poirier et al., 1991). When the sciatic
nerve was injured, macrophages responding to the injury rapidly
began secreting very large quantities of apoE (200-fold over the
level seen in the uninjured nerve) and ‘‘capturing’’ the lipids in
the local environment of the injured nerve. ApoE–lipid complexes
were shown to be delivered to the growth cones of the regener-
ating nerves and to Schwann cells for myelin formation through
lipoprotein receptor uptake. The secretion-capture process
has been further established in the liver, where apoE captures
lipoproteins and targets them for receptor-mediated uptake.
In fact, apoE secreted by hepatocytes and macrophages has
been shown to bind to cell-surface heparan sulfate proteogly-
cans where it is available to capture lipids and lipoproteins; the
heparan sulfate proteoglycans themselves acting as a receptor
or part of a receptor complex (Ji et al., 1994; Mahley and Ji,
1999). Thus, apoE secreted by injured neurons may be serving
this critical role in lipid redistribution in the repair process. Alter-
natively, or in addition, apoE may have a role in cell signaling, as
Figure 4. Models of the Structures of ApoE3 and ApoE4
(A) ApoE4 displays a unique property called domain interaction caused by the
ionic interaction between arginine-61 in the N-terminal domain with glutamic
acid-255 in the C-terminal domain. ApoE3 is significantly less likely to undergo
domain interaction than apoE4.
(B) ApoE4 domain interaction can be blocked by a small-molecule apoE4
structure corrector that disrupts the ionic interaction between arginine-61 and
glutamic acid-255. This converts apoE4 to an apoE3-like molecule both
structurally and functionally (Huang, 2010; Mahley and Rall, 2000; Mahley
et al., 2006, 2009). ApoE4SC, apoE4 structure corrector. Figure reprinted with
permission from Mahley and Huang (2012). Copyright 2012 American Chem-
ical Society.
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2002).
Although apoE may play an important role in repairing
damaged neuronal membranes, it is also associated with neuro-
degeneration. This assertion is supported by a vast array of
structural, molecular, cellular, and behavioral data showing
that the three isoforms of apoE display key variations in their
protein structure and stability that, in turn, differentially impact
neuropathology.
Structural Differences among the Isoforms Set the
Stage for Neuropathology
The single amino acid interchanges that distinguish the apoE
isoforms result in differences in protein stability as well as the
propensity to display a unique structural property called domain
interaction (Dong et al., 1994; Huang, 2010; Mahley et al., 2006;
Zhong and Weisgraber, 2009).
ApoE2 has a cysteine residue at position 158 whereas apoE3
and apoE4 each have arginine. While this substitution in apoE2
results in defective lipoprotein-receptor binding and the devel-
opment of the lipid disorder type III hyperlipoproteinemia (Mah-
ley, 1988; Mahley et al., 1999; Mahley and Rall, 2000), it also
confers greater protein stability, which likely is associated with
its protective effect against Alzheimer’s disease (AD).
ApoE4, which is strongly linked to AD (Roses, 1996), uniquely
possesses an arginine at residue 112, whereas both apoE2 and
apoE3 have cysteine at this site. This single amino acid differ-
ence in apoE4 is associated with protein instability and domain
interaction (Dong et al., 1994; Zhong and Weisgraber, 2009).
ApoE3, the most common isoform in humans, has a cysteine
residue at position 112 and an arginine at position 158, is more
stable than apoE4, and is less likely to display domain interaction
than apoE4.
As illustrated in Figure 4, in apoE4 the arginine at residue 112
causes the side chain of arginine-61 to be solvent exposed, to
extend away from the helical bundle in the N-terminal domain,
and to interact with glutamic acid-255 in the C-terminal domain
through ionic bonding. Although all isoformsmay display domain
interaction to some extent, the amino acid substitutions of apoE4
encourage domain interaction much more than the apoE3 and
apoE2 isoforms (apoE4 > apoE3 > apoE2). Importantly, this
apoE4 property has been established biophysically by fluores-
cence resonance energy transfer (FRET) and electron paramag-
netic resonance spectroscopy (Dong et al., 1994; Hatters et al.,
2005; Xu et al., 2004; Zhong and Weisgraber, 2009). The dis-
tance between arginine-61 and glutamic acid-255 was 10 A˚
in apoE4 and greater than 22 A˚ in apoE3 (Hatters et al., 2005).
Recently, the nuclear magnetic resonance structure for full-
length apoE3 was determined (Chen et al., 2011b). The structure
reveals a unique topology, which is postulated to shield the LDL
receptor-binding region by the C-terminal domain and prevent
binding to the receptor in the nonlipid form. However, in order
to prevent tetramer formation and aggregation, it was necessary
to introduce five nonconservative mutations into the C-terminal
domain (F257A/W264R/V269A/L279Q/V287E). Unfortunately,
these rather severe changes undoubtedly alter the C-terminal
domain and likely distort the conformation and intramolecular
interactions with this domain. Thus, the nuclear magnetic reso-nance structuremay not represent a physiological and functional
structure of apoE.
In all, these data show how relatively minor changes in
apoE sequence yield significant differences in apoE’s ability to
promote neuronal health versus neuronal damage, especially
when apoE synthesis is increased after injury. The apoE hypoth-
esis therefore suggests that the isoform-dependent neuronal
response to increased apoE expression is a critical step in laying
the groundwork for future pathology. In the following sections,
we describe the apoE4-specific effects on neuronal function
and how they affect neuronal integrity at the cellular level.
Impaired Neuronal Intracellular Trafficking of ApoE
(ApoE4 > ApoE3)
Fluorescence recovery after photobleaching experiments re-
vealed impaired intracellular trafficking of apoE4 through the
ER and Golgi apparatus in cultured cells (Brodbeck et al.,
2011). Neuro-2a cells expressing EGFP-apoE3 or EGFP-apoE4
were photobleached with an argon laser, and the extent and
rate of recovery of fluorescence were used as a measure of
transit through the secretory pathway. Although the trafficking
of apoE4 through the ER and Golgi apparatus was significantly
impaired compared with apoE3 (Figure 5A), blocking domainNeuron 76, December 6, 2012 ª2012 Elsevier Inc. 875
Figure 5. ApoE4 Displays Impaired
Trafficking through the Secretory Pathway
that Can Be Corrected by Blocking ApoE4
Domain Interaction
Fluorescence recovery after laser photobleaching
experiments were performed on EGFP-apoE3-
and EGFP-apoE4-expressing Neuro-2a cells. For
each section, the left and center panels show
representative recovery curves for the ER and
Golgi apparatus, respectively, while the right-hand
panel shows quantitative histograms of apoE
mobility.
(A) Recovery curves show that apoE4 trafficking is
decreased compared with apoE3 in both the ER
(left) and Golgi apparatus (center). Right, histo-
gram showing that the percent of the immobile
fraction was greater with apoE4 than apoE3.
(B) The impaired trafficking of apoE4 was reversed
by site-directed mutagenesis of arginine-61,
which blocked domain interaction (apoE4-R61T).
This mutation reversed the impairment in apoE4
trafficking and mobility in both the ER and Golgi
apparatus.
(C) Treatment of apoE4-expressing cells with
a structure corrector (PH-002) restored the traf-
ficking of apoE4 through the secretory pathway.
The structure corrector did not affect the traf-
ficking of apoE3 or apoE4-R61T. Modified from
Brodbeck et al. (2011). Copyright the American
Society for Biochemistry and Molecular Biology.
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nine-61 to threonine) or by exposure to small-molecule structure
correctors restored normal trafficking properties to apoE4
(Figure 5B and 5C) and led to decreased neurotoxic fragment
formation. These domain interaction-blocking approaches will
be discussed in more detail below. Thus, it is envisioned that
(1) the impaired transit of apoE4 occurs because of its abnormal
structure, because blocking domain interaction restores the
transit, (2) the abnormal structure and trafficking likely target
the protein for proteolysis, and (3) small-molecule structure
correctors likely target apoE as it is synthesized or soon after
entering the ER lumen. Such findings suggest that one way to
resolve the negative effects of apoE4 expression is to convert
apoE4’s structure to be more apoE3-like.
ApoE (ApoE4 > ApoE3) Susceptibility to Neuron-Specific
Proteolysis and theGeneration of Neurotoxic Fragments
The cellular mechanisms and organelles that promote the clear-
ance of abnormally folded proteins are ubiquitous, and abnormal
forms of apoE, especially apoE4, can indeed be targeted for
proteolysis. In fact, neurotoxic fragments are generated only
by neurons, and not by astrocytes or other apoE-synthesizing
cells (Brecht et al., 2004; Harris et al., 2003; Huang et al.,
2001). Why, then, are neurons less effective than other cell types
at completely degrading and clearing misfolded apoE? It is
possible that, because apoE is an avid lipid-binding protein,
lipid-based interactionsmay protect some domains fromproteo-
lytic cleavage, thus resulting in the accumulation of a spectrum
of neurotoxic fragments. While full-length apoE is 34 kDa, a frag-
ment pattern of bands ranging from 29–30 kDa to 12–14 kDa is
consistently seen in extracts from cultured neurons expressing
apoE4, apoE4 transgenic mice and in the brains and cerebro-876 Neuron 76, December 6, 2012 ª2012 Elsevier Inc.spinal fluid from humans with AD (Brecht et al., 2004; Harris
et al., 2003; Huang et al., 2001; Jones et al., 2011). Furthermore,
more of these fragments are observed in AD patients expressing
the apoE4 allele compared with normal, nondemented apoE4-
carrying humans (Figure 6; Harris et al., 2003; Jones et al., 2011).
Although the unique protease that is responsible for apoE4
fragmentation remains to be identified, it is thought to be a
chymotrypsin-like serine protease (Harris et al., 2003). This pro-
tease, most likely residing in the ER or Golgi apparatus, gener-
ates the unique series of fragments ranging from 29–30 kDa
to 12 kDa (Huang, 2010; Huang and Mucke, 2012; Mahley
et al., 2006). The 29–30 kDa fragments result from cleavage at
methionine-272 and leucine-268, respectively, and subsequent
cleavage results in the generation of smaller fragments, primarily
in the 12–20 kDa range. All of the neurotoxic fragments lack the
C-terminal 27–30 amino acids and contain the lipid-binding
region of apoE (residues 240–270) (Brecht et al., 2004; Chang
et al., 2005; Harris et al., 2003; Huang et al., 2001; Jones et al.,
2011). In addition to containing the lipid-binding region, the neu-
rotoxic fragments also contain the LDL receptor-binding region
of apoE (residues 136–150). The secondary cleavage events
remove varying lengths of peptide from the N terminus. As
mentioned above, these fragments are generated in the ER or
Golgi apparatus, and yet many of their effects are seen in the
cytosol. The cleavage of the C terminus allows this translocation
and several of the subsequent cytosolic effects.
ApoE Fragments Escape the Secretory Pathway and
Enter the Cytosol
How do the apoE4 fragments generated by neuron-specific
proteolysis leave the ER or Golgi compartments and enter the
cytosol? Cleaving off the C-terminal 27–30 amino acids exposes
Figure 6. ApoE Fragmentation Pattern in Human Temporal Cortex in
Nondemented Controls and in Age-Matched AD Patients
Compared with full-length apoE (34 kDa), proteolytic cleavage generates an
initial fragment with a molecular weight of 29 kDa. Subsequent to this,
fragments of 12–20 kDa are generated. In AD patients, there is an apoE4
gene-dose effect on apoE fragmentation, whereby apoE4/3 subjects have
more fragments than apoE3/3 subjects and the apoE4/4 subjects have the
greatest amount of fragments.
Figure 7. Regions of ApoE Responsible for Fragment Translocation
into the Cytosol, Mitochondrial Targeting, and Neurotoxicity
Fragments containing the receptor-binding region (residues 136–150) and the
lipid-binding region (residues 240–270) represent the minimal structure re-
quired for translocation, mitochondrial localization, and neurotoxicity. Modi-
fied from Mahley et al. (2006). Copyright the National Academy of Sciences.
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protein. This allows for apoE4 translocation into the cytosol,
thereby facilitatingmitochondrial localization and causing neuro-
toxicity (Chang et al., 2005). However, deletion of the lipid-
binding region (residues 240–270) in a fragment encompassing
residues 1–191 did not inhibit translocation into the cytosol,
but this fragment also did not interact with mitochondria or
cause neurotoxicity. Finally, removal of the portion of apoE that
includes the LDL receptor-binding region (residues 136–150)
prevented translocation (Figure 7), as did mutations of critical
arginine and lysine residues in this region (Chang et al., 2005).
These studies show that a minimal structure supporting trans-
location, mitochondrial localization, and neurotoxicity requires
the presence of both the receptor- and lipid-binding regions of
apoE (Chang et al., 2005). The charged arginine and lysine
residues in the 136–150 region are critical for translocation, a
region that is similar to the protein-translocation domains of
other proteins, including viral proteins. The hydrophobicity of
the lipid-binding region (residues 240–270) is certainly involved
in mitochondrial interaction and subsequent neurotoxicity,
because mutation of critical conserved residues in this region,
or deletion of this region altogether, blockedmitochondrial local-
ization. Importantly, these truncation variants generated in the
laboratory are likely counterparts to the spectrum of toxic frag-
ments observed in the brain (Figure 6) and cerebrospinal fluid
of human AD patients, making the results highly relevant to our
understanding of human AD pathology.
ApoE4-Associated Neuronal Mitochondrial Dysfunction
Mitochondrial dysfunction is a hallmark of several neurodegen-
erative diseases, including AD (Atamna and Frey, 2007; Parihar
and Brewer, 2007). Functional brain imaging with fluorodeoxy-
glucose (18F), a radiotracer used to study glucose utilization as
a surrogate measure of mitochondrial activity, revealed that the
cerebral metabolic rate was reduced in both AD patients and
in cognitively normal apoE4 carriers in their 20s and 30s, several
decades before the typical onset of dementia (Reiman, 2007;
Reiman et al., 2004). Gene-expression profiles in postmortemhuman brain tissue showed a significant association between
apoE genotype and the expression levels of multiple mitochon-
drial respiratory enzymes (Conejero-Goldberg et al., 2011),
specifically, a reduction in the expression of electron transport-
chain genes in apoE4 carriers (Liang et al., 2008). These results
suggest that in humans, apoE genotype can influence brain
metabolism and possibly mitochondrial function and that alter-
ations in these processes may be linked to the onset and/or
progression of AD.
We have shown that primary neurons from apoE4 transgenic
mice had reduced levels of numerous mitochondrial respiratory
enzymes compared with apoE3-expressing cells (Chen et al.,
2011a). However, there were no differences in the mitochondrial
complexes in astrocytes expressing apoE4 driven by the glial
fibrillary acidic protein promoter, revealing that apoE4’s effects
are neuron specific. In addition, apoE4 expression in Neuro-2a
cells led to reduced levels of mitochondrial complexes I, IV,
and V, as well as a reduction in functional respiratory capacity
(Chen et al., 2011a). The addition of an uncoupling agent led to
a 98% increase in the maximal oxygen-consumption rate in
apoE3-expressing cells compared with only a 50% increase in
the apoE4-expressing cells (Chen et al., 2011a).
In cells transfected with the apoE4 variant lacking the
C-terminal 27 amino acids, the fragment was found to be
expressed in a granular distribution that localized preferentially
to mitochondria (Chang et al., 2005); this led to mitochondrial
dysfunction, as demonstrated by loss of membrane integrity
and electropotential. Again, the active fragments that altered
mitochondrial membrane electropotential contained the recep-
tor- and lipid-binding regions. Nakamura et al. (2009) demon-
strated that apoE4 lacking the C-terminal 27 amino acids bound
directly to several components of the electron transport-chain
enzymes and reduced respiratory activity. Likewise, apoE4,
and especially the apoE4 fragments, have been shown to impair
mitochondrial dynamics and synaptogenesis (Brodbeck et al.,
2011; Chen et al., 2012). For example, mitochondrial motility
was reduced by 35% and 57% by apoE4 and apoE4 fragments
lacking the C-terminal 27 amino acids, respectively, in trans-
fected PC12 cells. Furthermore, dendritic spine densities were
reduced in apoE4-expressing primary neurons by 26% and in
apoE4 fragment-expressing neurons by 46%, compared withNeuron 76, December 6, 2012 ª2012 Elsevier Inc. 877
Neuron
PerspectiveapoE3 (Brodbeck et al., 2008). These abnormalities, which could
be related tomitochondrial dysfunction, were domain-interaction
dependent, as these effects could be reversed by either blocking
domain interaction by site-directed mutagenesis (apoE4-R61T)
or by treatment with small-molecule structure correctors.
How andwhere the apoE fragments interact withmitochondria
remains to be determined. As discussed, themitochondrial bind-
ing of apoE fragments requires the absence of the C terminus
and the presence of the lipid-binding region. The unique lipid
composition of mitochondria could allow the fragments to
interact directly with the mitochondrial surface through a hydro-
phobic lipid interaction. On the other hand, there are numerous
mitochondrial outer membrane proteins, the function of which
could be altered by an interaction with apoE fragments. For
example, apoE fragment interaction with the voltage-dependent
anion channel (also known as mitochondrial porin), which con-
trols the entry and exit of mitochondrial metabolites, could
disrupt multiple functions ascribed to this channel (Shoshan-
Barmatz et al., 2010).
A link between apoE and a specific mitochondrial protein has
been suggested. In AD patients, Roses (2010) demonstrated an
age-of-onset-associated polymorphism in the translocase of the
outer mitochondrial-membrane (TOMM40) gene, which is in the
region of the apoE locus and is in strong linkage disequilibrium.
Variable-length poly-T polymorphisms appear to alter the age-
of-onset of AD. For example, apoE3, in the context of the longer
TOMM40 poly-T repeats, is associated with an earlier age-of-
onset than apoE3 individuals with shorter repeats. Such poly-
morphisms could modulate the apoE isoform-specific effects
on AD. TOMM40 is a part of the mitochondrial machinery
that controls protein translocation into the mitochondria (Kutik
et al., 2007; Pfanner and Wiedemann, 2002; Rapaport, 2005).
Specific pre- or internal sequences within a protein, or interac-
tions with transfer chaperones—such as HSP90- and HSP70-
class chaperones—participate in the recognition and transloca-
tion of proteins into themitochondria. It has been postulated that
apoE-TOMM40 protein interactions may alter mitochondrial
function, possibly causing cytochrome c release and apoptosis
(Roses, 2010). This observation has been confirmed in some
studies but not in others (Cruchaga et al., 2011; Maruszak
et al., 2012). In fact, a recent large study of more than 11,000
AD patients and 10,000 cognitively normal controls from 15
genome-wide association studies demonstrated that the apoE
alleles (ε2, ε3, and ε4) accounted for essentially all the risk and
age-of-onset of AD (Jun et al., 2012). The inherited susceptibility
was not associated with neighboring genes, including TOMM40
and apoC1. These data suggest that the genetic role of TOMM40
should be reassessed; thus, the mechanism whereby apoE
alters mitochondrial function remains to be determined.
ApoE-Associated Alterations in the Neuronal
Cytoskeleton
The neuronal cytoskeleton is composed of microtubules, neu-
rofilaments, and microfilaments. Microtubules, polymeric struc-
tures composed of a- and b-tubulin, are critical for neurite
extension and organelle trafficking, including the distribution of
mitochondria to the sites of newly forming synapses. They are
associated with a heterogeneous set of microtubule-associated878 Neuron 76, December 6, 2012 ª2012 Elsevier Inc.proteins, including tau, that modulate their structure and func-
tion. Until recently, the major function of tau was thought to be
its ability to stabilize microtubules (Lee et al., 2001; Morris
et al., 2011; Sydow et al., 2011). Now, it appears that its role
may be more dynamic, possibly participating in intracellular
signal transduction, among other roles. Importantly, tau is highly
susceptible to hyperphosphorylation and the formation of
intracellular NFTs, both of which are hallmark neuropathologies
that critically promote the damage observed in AD and TBI
(McKee et al., 2009; Morris et al., 2011).
ApoE4 Alters Neuronal Microtubules and Impairs
Neurite Outgrowth
ApoE4 has been shown to directly alter microtubule structure
and to stimulate tau hyperphosphorylation and NFT formation
(Huang, 2010; Huang and Mucke, 2012). Exposure of neuronal
cultures to exogenous apoE4-lipid complexes caused significant
cytoskeletal disruption and impaired neurite outgrowth com-
pared with apoE3-containing complexes (Bellosta et al., 1995;
Nathan et al., 1994; Nathan et al., 1995). ApoE4-treated Neuro-
2a cells also had fewer intracellular microtubules, as identified
by immunocytochemical localization of b-tubulin and by electron
microscopy (Nathan et al., 1995), and these effects were associ-
ated with impaired neurite outgrowth in apoE4-treated cells.
These results were replicated in apoE3- or apoE4-transfected
Neuro-2a cells expressing nanogramquantities of apoE (Bellosta
et al., 1995).
ApoE4 Stimulates Tau Phosphorylation and NFT-like
Formation
Increased tau phosphorylation has been observed in transgenic
mice expressing apoE4 in neurons, but not in those expressing
apoE4 in astrocytes, suggesting a cellular source-dependent
effect of apoE4 on tau phosphorylation (Harris et al., 2003;
Tesseur et al., 2000), occurring in parallel with the generation of
apoE fragments in neurons (Andrews-Zwilling et al., 2010; Harris
et al., 2003). There is evidence that apoE4 stimulates tau phos-
phorylation by activating the extracellular signal-regulated pro-
tein kinase pathway in the hippocampus (Harris et al., 2004a),
although other signaling pathways may also be involved. Intra-
neuronal phospho-tau inclusions are prominent in the hippo-
campus and form NFT-like structures composed of apoE4,
phospho-tau, and neurofilaments; by electronmicroscopy, these
inclusions are visualized as tightly packed, straight filaments that
closely associate with mitochondria (Harris et al., 2003).
In addition to such insights into the cell biological impacts of
apoE fragments, transgenic animal experiments are uncovering
how this neurotoxicity at the cellular level corresponds to
neuronal function and behavior.
Neurotoxic Effects of ApoE Fragments
The expression of truncated apoE4 in transgenic mice provides
insights into how and where the fragments cause neurotoxicity.
Transgenic mice expressing a variant of apoE4 that lacks the
C-terminal 27 amino acids (apoE4[1–272]), driven by the Thy1.2
promoter, had significant hippocampal neurodegeneration and
neuronal loss (Harris et al., 2003). However, not every fragment
of apoE is toxic, because expression of apoE4(1–240)—the
form lacking the lipid-binding region—was not found to trigger
hippocampal neurodegeneration. The loss of hippocampal
Figure 8. ApoE4-Transfected Cells
Demonstrate Intracellular FRET Signal
ApoE constructs were generated to express YFP
andCFP at theN andC termini, respectively, to act
as reporter FRET fluorophores. When expressed
in Neuro-2a cells, YFP-apoE4-CFP displays sig-
nificantly more FRET signal compared to YFP-
apoE3-CFP-expressing cells. This reflects the
closer interaction between the N- and C-terminal
domains in apoE4 and demonstrates that the
biophysical property of domain interaction
occurs in cells. Modified from Xu et al. (2004).
Copyright the American Society for Biochemistry
and Molecular Biology.
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impaired learning and memory behaviors as early as 6 months
of age, as assessed by the Morris water maze test (Andrews-
Zwilling et al., 2010;Harris et al., 2003). Likewise,when full-length
apoE4 was specifically expressed in neurons (NSE-apoE4
transgenic mice), these mice displayed early-onset impaired
learning and memory (Buttini et al., 1999; Raber et al., 1998;
Raber et al., 2000) that correlated with multiple neuropatho-
logical effects, including loss of synaptic connections and
neurodegeneration (Buttini et al., 1999). These effects are likely
mediated through apoE4 fragment generation (Brecht et al.,
2004). In addition to neurodegenerative changes in the brain,
the apoE4(1–272) mice display other pathologies in the hippo-
campus, including NFT structures rich in hyperphosphorylated
tau, which were elevated by about six-fold over levels seen in
nontransgenic mice (Andrews-Zwilling et al., 2010; Harris et al.,
2003).
ApoE Fragments Induce Neuropathology in Specific
Neuronal Subtypes
Andrews-Zwilling et al. (2010) showed that apoE4 knock-in mice
display an age-dependent decrease in GABAergic interneurons
selectively in the hilus of the hippocampus and that this decrease
was associated with impaired learning and memory behaviors
in these mice. Transgenic expression of an apoE4 truncation
mutant lacking the C-terminal 27 amino acids led to an even
more marked decrease in GABAergic interneuron levels, along
with pronounced hyperphosphorylation of tau in the hippo-
campus (Andrews-Zwilling et al., 2010). Studies by Li et al.
(2009) have also revealed a link between apoE4 expression
and the impaired generation of new neurons, demonstrating
that apoE4 knockin mice have reduced hilar GABAergic inter-
neurons, leading to impaired hippocampal neurogenesis. Based
on these data, it has been postulated that the parallel decreases
in interneuron levels and hippocampal neurogenesis are respon-
sible for the behavioral impairments seen in apoE4 transgenic
mice (Andrews-Zwilling et al., 2010; Huang and Mucke, 2012;
Li et al., 2009). In support of this hypothesis, optogenetic manip-Neuron 76,ulations of hilar GABAergic interneurons
confirmed that functional inhibition of
this specific neuronal population results
in spatial learning and memory deficits,
as seen in apoE4 knockin mice (An-
drews-Zwilling et al., 2012).These effects on hippocampal GABAergic neurons and
memory behaviors are consistent across studies, but nonethe-
less reveal interesting differences depending on whether apoE4
is expressed selectively in neurons versus ubiquitously in the
brain. For example, apoE4 knockin mice showed impaired learn-
ing and memory behaviors, but at a later time point (16 months
of age) compared with neuron-specific (i.e., Thy1.2- or NSE-
promoter-driven) apoE4 mice (Andrews-Zwilling et al., 2010).
Although not directly proven, it is reasonable to speculate that
the delayed impairment in the apoE4 knockin mice reflects the
age-related and comparatively delayed accumulation of neuro-
toxic fragments in neurons, while neuron-specific apoE-express-
ing mice accumulate these fragments much earlier.
Having uncovered many of the isoform-specific detrimental
effects of apoE, new findings examine whether such effects
can be reversed by correcting apoE4’s abnormal protein struc-
ture, an approach that can potentially open new avenues for
therapeutics.
Domain Interaction In Vitro and In Vivo
Interestingly, all animal species except humans have threonine
at the site equivalent to residue 61 (Mahley and Rall, 2000; Weis-
graber, 1994; Zhong and Weisgraber, 2009). Lower species do
not display isoforms, and almost all—including mice and rats—
have an arginine at the site equivalent to residue 158, making it
human apoE4-like in sequence. However, because these apoE
orthologs expressed in lower species lack an arginine-61 equiv-
alent, they also lack domain interaction. Thus, they are not equiv-
alent to either apoE3 or apoE4 structurally or functionally (Mahley
and Rall, 2000;Weisgraber, 1994; Zhong andWeisgraber, 2009).
Raffaı¨ et al. (2001) created a ‘‘humanized’’ apoE mouse line, in
which the threonine located at the residue equivalent to 61 in
human apoE was replaced by gene targeting with an arginine,
thus allowing mouse apoE to have domain interaction. Impor-
tantly, these mice developed some characteristics resembling
human apoE4 knockin mice, including loss of synaptic marker
immunolabeling in the hippocampus and a mild memory deficit
in the Morris water maze test (Zhong et al., 2008).December 6, 2012 ª2012 Elsevier Inc. 879
Figure 9. FRET Assay Identifies ApoE4 Structure Correctors
(A) The FRET signal is generated between the donor and acceptor fluo-
rophores conjugated to the N and C termini of apoE. ApoE4 gives a higher
FRET signal because of the closeness of the N- and C-terminal domains. The
apoE4 signal is reduced by the small-molecule apoE structure corrector (SC)
by disrupting domain interaction (Chen et al., 2012).
(B) Dose-response analysis reveals the relative potencies of three active and
one inactive structure corrector (Chen et al., 2012).
(C) Mitochondrial cytochrome c oxidase (COX1) is reduced in Neuro-2a cells
expressing apoE4 comparedwith apoE3. A small-molecule structure corrector
(CB9032258) corrects the COX1 deficiency in the apoE4-expressing cells, but
does not significantly affect apoE3-expressing cells.
(A) and (B)Modified fromChen et al. (2012). Copyright the American Society for
Biochemistry and Molecular Biology.
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block apoE4 domain interaction using cellular FRET assays
(Chen et al., 2012; Mahley and Huang, 2012). Additional assays
were also used to establish the downstream functional effects of
blocking apoE4 domain interaction with structure correctors
(Brodbeck et al., 2011; Chen et al., 2011a, 2012).
The FRET assay to measure domain interaction relied on the
creation of human apoE variants tagged at both the N and
C termini with fluorescent constructs. When we tagged either
apoE3 or apoE4 with yellow fluorescent protein (YFP) at the
N terminus and cyan fluorescent protein (CFP) at the C terminus
and transfected these constructs into Neuro-2a cells, we ob-
served significantly enhanced FRET signal in the apoE4-ex-
pressing cells compared with their apoE3-expressing counter-
parts (Figure 8; Xu et al., 2004), confirming that this FRET
approach can detect apoE4 domain interaction, and that domain
interaction is a property of apoE4 that occurs intracellularly.
In a complementary set of assays (Chen et al., 2012), apoE4
was instead tagged with GFP at the N terminus and E. coli dihy-
drofolate reductase (eDHFR) at the C terminus. The construct
was expressed in Neuro-2a cells, and an eDHFR high-affinity
ligand (trimethoprim) conjugated with hexachlorofluorescein
served as the acceptor fluorophore. The GFP-apoE4-eDHFR
gave a significantly higher FRET signal than the apoE3 construct,
reflecting a closer proximity of the N- and C-terminal domains in
apoE4 (Chen et al., 2012). Furthermore, a screen for small mole-
cules capable of blocking domain interaction identified several
that dose-dependently decreased the FRET signal (Figures 9A
and 9B; Chen et al., 2012), serving as proof-of-concept that
apoE4 is a promising target for the development of small mole-
cule–based therapeutics.
Detrimental Effects of ApoE4 Can Be Reversed by
Blocking Domain Interaction
Blocking domain interaction in apoE4 reverses many of its detri-
mental effects, both in vitro and in vivo (Mahley and Huang,
2012). This can be accomplished by site-directed mutagenesis
in which arginine-61 is exchanged for threonine, thereby pre-
venting the ionic interaction, or by small-molecule structure
correctors that interact with apoE in the vicinity of arginine-61
to prevent or retard domain interaction.
Importantly, blocking domain interaction by site-directed
mutagenesis or small-molecule structure correctors markedly
reduced proteolysis and fragment formation. Mitochondrial
dysfunction was no longer observed in cells expressing an
apoE4 variant that lacked the ability to undergo domain interac-
tion (apoE4-R61T). Furthermore, a small-molecule structure
corrector restored the level of complex IV mitochondrial cyto-
chrome c oxidase in apoE4-expressing cells to levels seen in
apoE3-expressing cells (Figure 9C; Chen et al., 2012). These
studies were expanded to identify potent apoE4 structure
correctors that could restore the level of mitochondrial cyto-
chrome c oxidase with the potential to be used in vivo. A class
of such small-molecule compounds that displays a significant
structure-activity relationship has been identified (Chen et al.,
2012).
As described, blocking apoE4 domain interaction restores
neurite outgrowth, mitochondrial motility, and synaptic density
Figure 10. ApoE Sets the Stage and
Response to Neuronal Injury Triggers
Neuropathology
(1) Injury to neurons induces the synthesis of apoE.
ApoE (apoE4 > apoE3) is susceptible to proteolytic
cleavage in neurons, and the neurotoxic frag-
ments that are generated escape the secretory
pathway and causemitochondrial dysfunction and
cytoskeletal alterations. This is most likely to occur
when apoE4 is expressed (apoE4 > apoE3) due to
its abnormal protein conformation (instability and
domain interaction). (2) Exogenous apoE, primarily
from astrocytes, could cause neuronal injury and
could generate neurotoxic fragments by being
shunted to the ER/Golgi apparatus, where prote-
olysis could occur. In addition, exogenous apoE
does impact Ab clearance/deposition. (3) Ab ex-
pression can be induced by injured/stressed
neurons, and together with other injurious agents
could perpetuate the toxic cycle of injury in neu-
rons. This would include apoE synthesis followed
by proteolytic cleavage, toxic fragment formation,
and neuropathology.
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interaction is a critical structural element that modulates both the
physiological and pathophysiological functions of apoE4 (Mah-
ley and Huang, 2012).Hypothesis: ApoE Sets the Stage and Response to
Neuronal Injury Triggers Neuropathology
The studies reviewed here, which comprise only a subset of the
work done on apoE4 in the central nervous system, overwhelm-
ingly point to a critical direct role for apoE4 in AD-mediated neu-
rodegeneration. Based upon these studies, we propose the
following model (Figure 10) to illustrate this hypothesis.
Figure 10 (1): What is well established is that neuronal injury or
stress, caused by a variety of injurious agents, induces the
synthesis of apoE by neurons. The structural properties of
each apoE isoform dictate its propensity to undergo domain
interaction (apoE4 > apoE3 > apoE2), which leads to apoE
isoform-dependent proteolysis and the generation of neuro-
toxic fragments. In turn, these fragments causemitochondrial
dysfunction and cytoskeletal alterations, leading to neurode-
generation (Huang, 2010; Huang and Mucke, 2012; Mahley
et al., 2006).
Figure 10 (2):What is clearlymore speculative iswhether there
is a direct effect of exogenous apoE4, i.e., astrocyte-derived
apoE, on neurons and neuropathology. In some studies,
exogenous apoE4 can have direct detrimental effects on
neurons, e.g., by inhibiting neurite outgrowth and mitochon-
drial motility (Chen et al., 2012; Nathan et al., 1994). Hartman
et al. (2001) demonstrated that apoE4, when produced by
astrocytes, impaired working memory but did not induce
AD-like neuropathology in mice. Whether internalized apoE
that is sequestered in endosomes escapes lysosomal degra-
dation, is transferred to theER/Golgi apparatus compartment,
and undergoes proteolysis and toxic fragment formation—or
whether exogenous apoE4 acts through another mechanismindependent of intracellular apoE fragment generation—is
unknown. For example, in hepatocytes and macrophages, it
has been established that apoE can escape lysosomal degra-
dation and reenter the secretory pathway (Farkas et al., 2003;
Fazio et al., 2000; Zhu et al., 2005). It is possible that the detri-
mental effects of apoE4 observed by Chen et al. (2010) in
neurons reflect the sequestration of apoE4 in endosomes
and recycling to the ER/Golgi apparatus, in addition to its
effects on N-methyl-D-aspartate receptors. Alternatively,
astrocyte-derived apoE4 might directly damage the integrity
of the BBB, allowing blood-derived proteins to enter the brain
and injure neurons, and setting up the detrimental response to
injury (Akassoglou et al., 2004; Bell et al., 2012). What is not
speculative, however, is that astrocytic apoE4 can negatively
impact Ab clearance and/or deposition (Bien-Ly et al., 2011;
Castellano et al., 2011; Kim et al., 2011) and thus induce the
apoE neurotoxic pathway.
Figure 10 (3): Although much is yet to be learned about the
regulation of Ab and its potential roles in normal neuronal
biology, it appears that Ab production can be stimulated by
injury to neurons through oxidative stress (Misonou et al.,
2000; Paola et al., 2000; Tamagno et al., 2002) and energy
deprivation (O’Connor et al., 2008; Velliquette et al., 2005).
For example, exposure to low concentrations of 4-hydroxy-
2,3-nonenal increased intracellular Ab production by 2- to
6-fold in NT2-differentiated cells (Paola et al., 2000). Further-
more, glucose deprivation in cultured cells and in vivo
in transgenic mice induces the phosphorylation of eIF2a
(a translation initiation factor), which increases BACE1 ac-
tivity (the rate-limiting enzyme involved in Ab production)
and elevates Ab levels (O’Connor et al., 2008). In addition,
it is well established that Ab injures neurons (Huang and
Mucke, 2012; Palop and Mucke, 2010; Selkoe, 2011), which,
based on our hypothesis, would stimulate apoE production,
induce apoE neurotoxic fragment formation, and further per-
petuate the toxic cycle.Neuron 76, December 6, 2012 ª2012 Elsevier Inc. 881
Neuron
PerspectiveConclusion
Although much remains to be understood about how apoE
function affects both health and disease states, it is clear that
apoE plays a critical role in the pathogenesis of many different
neurodegenerative diseases. This assertion is no surprise, given
apoE’s fundamental role in cellular lipid transport and metabo-
lism. However, its widespread expression also highlights how
apoE is exceptionally well poised to induce or accelerate neu-
ronal damage in apoE4-carrying individuals. The significant risk
posed by apoE4 expression, combined with its widespread
presence in the population and the ever-increasing average life-
span in which apoE4 carriers may suffer from its detrimental
effects—in AD, TBI, and possibly other neuropathological disor-
ders—underscore the enormous value that can come from
developing therapies to counter its neurotoxic effects.
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